Skip to Main
News

Cancer Research UK and Teon Therapeutics Advance New First-In-Class Cancer Drug Into Clinical Trial

Cancer Research UK and Teon Therapeutics, Inc. (Teon) today (Monday 1 March) announce that they have signed a collaboration agreement to progress the early phase clinical development of Teon’s first-in-class small molecule adenosine A2B receptor antagonist, TT-702.

Read More

Teon Therapeutics Completes $30 Million Series A Financing

Teon Therapeutics, a biopharmaceutical company developing small molecules that inhibit the immunosuppressive and cancer-promoting signaling pathways, today announced the completion of a $30M Series A financing. The financing was led by Oceanpine Capital with participation from additional new investors Oriza Ventures, Lifespan Investments, and former Gilead senior executives.

Read More

Teon Therapeutics Appoints Glen Giovannetti as Independent Board Member

Teon Therapeutics, a private biopharmaceutical company developing a focused portfolio of small molecules that modulate metabolic signaling pathways in the tumor microenvironment, today announced the appointment of Glen Giovannetti, to its board of directors. Glen brings over 36 years of leadership success, industry expertise and board governance credentials following his retirement from EY (Ernst & Young) in December 2020.

Read More

Teon Therapeutics Announces Approval for Collaboration with Cancer Research UK

Teon Therapeutics, a private biopharmaceutical company developing a focused portfolio of small molecules that modulate metabolic signaling pathways in the tumor microenvironment, today announced that Cancer Research UK, the world’s leading cancer charity dedicated to saving lives, has formally approved Teon’s TT-702 program to enter into a clinical collaboration.

Read More

Teon Therapeutics to Present at Solebury Trout Private Company Showcase on October 15, 2020

Teon Therapeutics, Inc. has been invited to present at the Fall Private Company Showcase hosted by Solebury Trout, BMO and Davis Polk which is being held virtually on October 15, 2020. Teon is scheduled to present on October 15 at 11:40am PT, with one-on-one meetings to be held throughout the conference.

Read More

Teon Therapeutics Appoints Biotech Veteran Louis Lange as Independent Board Member

Teon Therapeutics, a private biopharmaceutical company developing a focused portfolio of small molecules that modulate metabolic signaling pathways in the tumor microenvironment, today announced the appointed of Louis Lange, MD, PhD, to its board of directors. Dr. Lange is a renowned academic Chief of Cardiology and biotech veteran, having founded CV Therapeutics in 1992 and served as its Chairman, CEO and CSO.

Read More

Teon Therapeutics Appoints Ken Horne as President & Chief Operating Officer

Teon Therapeutics, a pharmaceutical company developing novel small molecules focused on GPCR targets for oncology indications, today announced the appointment of Ken Horne as President and Chief Operating Officer. With this appointment, Mr. Horne will take responsibility for operations, business development and fund raising for Teon Therapeutics.

Read More